An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5

Molecular Pharmacology

Volumn 73, Issue 3, 2008, Pages 855-867

  Andrews, Glen ^a   Jones, Carolyn ^a   Wreggett, Keith A ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN; BETA CHEMOKINE; BMS 397; CARBOXYLIC ACID DERIVATIVE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; PROBENECID; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL CELL; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CHIMERA; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG MECHANISM; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN INTERACTION; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION;

ALLOSTERIC SITE; AMINO ACID SEQUENCE; ANIMALS; CALCIUM SIGNALING; CELL LINE; CHEMOKINE CCL22; CHEMOKINE CCL5; CHEMOKINES, CC; CHO CELLS; CRICETINAE; CRICETULUS; DATA INTERPRETATION, STATISTICAL; HUMANS; INHIBITORY CONCENTRATION 50; KIDNEY; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; RECEPTORS, CCR4; RECEPTORS, CCR5; RECEPTORS, G-PROTEIN-COUPLED; RECOMBINANT PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID; TRANSFECTION;

EID: 40849124250     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.039321     Document Type: Article

References (40)

1. Ajuebor MN, Carey JA, and Swain MG (2006) CCR5 in T-cell mediated liver diseases: what's going on? J Immunol 177:2039-2045.
2. Baxter A, Johnson T, Kindon N, Roberts B, Steele J, Stocks M, and Tomkinson N (2003a), inventors; AstraZeneca AB, Baxter A, Johnson T, Kindon N, et al., assignees. Preparation of N-pyrazinylthiophenesulfonamides as chemokine receptor modulators. World patent WO2003051870. 2003 June 26.
3. Baxter A, Johnson T, Kindon N, Roberts B, and Stocks M (2003b), inventors; AstraZeneca AB, Baxter A, Johnson T, Kindon N, et al., assignees. Preparation of N-pyrazinylbenzenesulfonamides as their use in the treatment of chemokine mediated diseases such as asthma. World patent WO2003059893. 2003 July 24.
4. Baxter A, Kindon N, and Stocks M (2005), inventors; AstraZeneca AB, Baxter A, Kindon N, and Stocks M, assignees. Preparation of condensed N-pyrazinylsulfonamides as their use in the treatment of chemokine mediated diseases. World patent WO2005021513. 2005 March 10.
5. Birdsall NJM and Lazareno S (2005) Allosterism at muscarinic receptors: ligands and mechanisms. Mini Rev Med Chem 5:523-543.
6. Bockaert J, Marin P, Dumuis A, and Fagni L (2003) The 'magic tail' of G protein-coupled receptors: an anchorage for functional protein networks. FEBS Lett 546:65-72.
7. Brooks JC and Treml S (1983) Catecholamine secretion by chemically skinned cultured chromaffin cells. J Neurochem 40:468-473.
8. Business Insights Research (2005) The Emerging Drug Targets Outlook: An analysis of novel molecular targets to develop innovative new therapeutics. Available at: http://www.bi-interactive.com/index.aspx?Lang=en&listview= list&MainPage=renderMarketing&ReportID=293
9. Christopoulos A (2002) Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov 1:198-210.
10. 1- adrenergic receptor that are involved in coupling the receptor to G proteins. J Biol Chem 281:12896-12907.
11. Devereux J, Haeberli P, and Smithies O (1984) A comprehensive set of sequence analysis programs for the VAX. Nucleic Acids Res 12:387-395.
12. 1 muscarinic acetylcholine receptor and its implications for drug design. Bioorg Med Chem Lett 16:1217-1220.
13. Ferenczi K, Fuhlbrigge RC, Pinkus JL, Pinkus GS, and Kupper TS (2002) Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol 119:1405-1410.
14. 5,6F motif in the rhodopsin ground state and during activation. Proc Natl Acad Sci U S A 100:2290-2295.
15. Haringman JJ, Kraan MC, Smeets TJM, Zwinderman KH, and Tak PP (2003) Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Ann Rheum Dis 62:715-721.
16. Homey B, Steinhoff M, Ruzicka T, and Leung DYM (2006) Cytokines and chemokines orchestrate atopic skin inflammation. J Allergy Clin Immunol 118:178-189.
17. Ishida T and Ueda R (2006) CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci 97:1139-1146.
18. Horton RM, Hunt HD, Ho SN, Pullen JK, and Pease LR (1989) Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene 77:61-68.
19. Johnson Z, Power CA, Weiss C, Rintelen F, Ji H, Ruckle T, Camps M, Wells TNC, Schwartz MK, Proudfoot AEI, et al. (2004) Chemokine inhibition - why, when, where, which and how? Biochem Soc Trans 32:366-377.
20. Kazmierski W, Bifulco N, Yang H, Boone L, DeAnda F, Watson C, and Kenakin T (2003) Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors. Bioorg Med Chem 11:2663-2676.
21. Kim RB (2006) Transporters and drug discovery: why, when and how. Mol Pharm 3:26-32.
22. Krishna AG, Menon ST, Terry TJ, and Sakmar TP (2002) Evidence that helix 8 of rhodopsin acts as a membrane-dependent conformational switch. Biochemistry 41:8298-8309.
23. Kristiansen K (2004) Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. Pharmacol Ther 103:21-80.
24. Lehmann N, Alexiev U, and Fahmy K (2007) Linkage between the intramembrane H-bond network around aspartic acid 83 and the cytosolic environment of helix 8 in photoactivated rhodopsin. J Mol Biol 366:1129-1141.
25. Lu Z-L, Saldanha JW, and Hulme EC (2002) Seven-transmembrane receptors: crystals clarify. Trends Pharm Sci 23:140-146.
26. Mariani M, Lang R, Binda E, Panina-Bordignon P, and D'Ambrosio D (2004) Dominance of CCL22 over CCL17 in induction of chemokine receptor CCR4 desensitization and internalization on human Th2 cells. Eur J Immunol 34:231-240.
27. Mellentin-Michelotti J, Evangelista LT, Swartzman EE, Miraglia SJ, Werner WE, and Yuan P-M (1999) Determination of ligand binding affinities for endogenous seven-transmembrane receptors using fluorometric microvolume assay technology. Anal Biochem 272:182-190.
28. Palani A, Shapiro S, Clader JW, Greenlee WJ, Cox K, Strizki J, Endres M, and Baroudy BH (2001) Discovery of 4-[(Z)-(4-bromophenyl)-ethoxyimino) methyl]-1′-[(2,3-dimethyl-3-pyridinyl)carbonyl]-4′-methyl-1, 4′-bipiperidine-N-oxide (SCH 351125): an orally bio-available human CCR5 antagonist for the treatment of HIV infection. J Med Chem 44:3339-3342.
29. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, et al. (2000) Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289:739-745.
30. Panina-Bordignon P, Papi A, Mariani M, Di Lucia P, Casoni G, Bellettato C, Buonsanti C, Miotto D, Mapp C, Villa A, et al. (2001) The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics. J Clin Invest 107:1357-1364.
31. Prahalad S (2006) Negative association between the chemokine receptor CCR5-Delta32 polymorphism and rheumatoid arthritis. Genes Immun 7:264-268.
32. Proudfoot AE (2002) Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2:106-115.
33. Purandare AV (2004), inventor; Bristol-Myers Squibb and Purandare AV, assignees. Preparation of piperazines as chemokine receptor antagonists. World patent WO2004020584. 2004 March 11.
34. Purandare AV and Somerville JE (2006) Antagonists of CCR4 as immunomodulatory agents. Curr Top Med Chem 6:1335-1344.
35. Saeki T (2004) Small-molecule chemokine receptor antagonists: potential targets for inflammatory and allergic disorders. Curr Med Chem - Anti-Inflam Anti-Aller Agents 3:363-375.
36. Schertler GF (2005) Structure of rhodopsin and the metarhodopsin I photointermediate. Curr Opin Struct Biol 15:408-415.
37. -/- mice. FASEB J 16:1313-1315.
38. Springael J-Y, Urizar E, and Parmentier M (2005) Dimerization of chemokine receptors and its functional consequences. Cytokine Growth Factor Rev 16:611-623.
39. 2-dopamine receptor of the bovine anterior pituitary gland. Mol Pharmacol 26:214-227.
40. Wreggett KA and Wells JW (1995) Cooperativity manifest in the binding properties of purified cardiac muscarinic receptors. J Biol Chem 270:22488-22499.